Phaseline

Companies › Resolve Therapeutics

Resolve Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RSLV-132
Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to hu
RNASE1Phase 2Primary Sjögren SyndromeMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06440525RSLV-132Phase 2Primary Sjögren SyndromeImmunologyMay 2027

Targets

RNASE1 (1)

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Elevara Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.